医脉通编译整理，未经授权请勿转载。

 

2021美国心脏协会科学年会（AHA 2021）将于2021年11月13日至15日在线上举行，将在3天内举办7个 late-breaking science sessions（LBS）专场。近日，AHA预告了今年年会的LBS专场信息。

最新研究包括里程碑式的EMPEROR-Preserved试验的最新数据（恩格列净用于射血分数保留的心衰患者）；PREPARE-IT 2试验（Icosapent ethyl用于COVID-19门诊患者），Fitbit心脏试验（该研究提供了使用Fitbit可穿戴设备患者检测房颤的数据）等。

 

LBS1：心胸外科的瓣膜、静脉和新观点

 

1.Aortic Valve Replacement Versus Watchful Waiting in Asymptomatic Severe Aortic Stenosis: The Avatar Trial (AVATAR)

AVATAR试验：在无症状严重主动脉瓣狭窄患者中，主动脉瓣置换术 vs 观察等待

 

2.Evaluating the Benefit of Concomitant Tricuspid Repair During Mitral Valve Surgery

评估二尖瓣手术合并三尖瓣修复的获益

 

3.A Randomized Study of Early Versus Standard Coronary Artery Bypass Surgery Among Patients Presenting With Acute Coronary Syndromes Treated With Ticagrelor (RAPID CABG)

RAPID CABG试验：接受替格瑞洛治疗的急性冠状动脉综合征患者早期与标准冠状动脉搭桥手术的随机研究

 

4.Efficacy and Safety of an External Support Device for Saphenous Vein Coronary Bypass Grafts: The VEST Trial

VEST试验：大隐静脉冠状动脉旁路移植术外部支撑装置的有效性和安全性

 

LBS 2：高血压对局部地区、全球和大流行的影响

 

1.A Remotely DeliveredHypertensionand Lipid Program in 10,000 Patients Across a Diverse Health Care Network

远程高血压和血脂项目：通过多元化的医疗保健网络为10000例患者提供服务

 

2.Disruption in Blood Pressure Control with the COVID-19 Pandemic: A Study of 24 U.S. Health Systems in the PCORnet Blood Pressure Control Laboratory (BP Track)

BP Track试验：PCORnet血压控制实验室通过对24个美国卫生系统进行研究，来探究Covid-19大流行对血压控制的破坏

3.A Cluster Randomized Trial of a Village Doctor-Led Intervention on Blood Pressure Control: China Rural Hypertension Control Project (CRHCP)

中国农村高血压控制项目（CRHCP）：乡村医生主导的干预血压控制集群随机试验

 

LBS 3：房性心律失常的预防与干预

 

1.The Coffee and Real-Time Atrial and Ventricular Ectopy (CRAVE) Trial

CRAVE试验：咖啡与实时房早和室早

2.Dabigatran Versus Warfarin on Cognitive Outcomes in Nonvalvular Atrial Fibrillation: Results of the GIRAF Trial

GIRAF试验：在非瓣膜性房颤患者中，达比加群 vs 华法林对认知结果的影响

3.Posterior Left Pericardiotomy Reduces Postoperative Atrial Fibrillation After Cardiac Surgery (PALACS)

PALACS试验：在心脏手术后进行左后心包切开术或可减少房颤的发生

 

4.Outcomes of Adjunctive Left Atrial Appendage Ligation Utilizing the LARIAT Compared to Pulmonary Vein Antral Isolation Alone: The AMAZE Trial

AMAZE试验：与单独肺静脉窦隔离相比，使用LARIAT辅助左心耳结扎术的结局

 

LBS 4：信息超负荷？致力于通过数字健康和自动化数据来改善护理服务

 

1.Risk Evaluation and its Impact on Clinical Decision-Making and Outcomes in Heart Failure: The REVeAL-HF Trial

REVIEW HF试验：心衰患者的风险评估及其对临床决策和结局的影响

 

2.Detection of Atrial Fibrillation in a Large Population Using Wearable Devices: The Fitbit Heart Study

Fitbit心脏研究：使用可穿戴设备在大量人群中检测房颤

3.Testing Individualized Triggers of Atrial Fibrillation: A Randomized Controlled Trial (I-STOP-AFib)

I-STOP-AFib随机对照试验：检测房颤的个体化触发因素

 

LBS 5：建立在治疗的基础上：心衰治疗的进展

1.Heart Failure With a Preserved Ejection Fraction 50% - Results From the EMPEROR-Preserved Clinical Trial

来自EMPEROR-Preserved试验的结果：射血分数保留的心衰（≥50%）

 

2.The Canagliflozin Impact on Health Status, Quality of Life and Functional Status in Heart Failure (CHIEF-HF) Clinical Trial

CHIEF-HF临床试验：卡格列净对心衰患者健康状况、生活质量和功能状态的影响

3.Efficacy and Safety of Empagliflozin in Hospitalized Heart Failure Patients: Main Results From the EMPULSE Trial

 EMPULSE试验的主要结果：恩格列净在住院心衰患者中的疗效和安全性

 

4.Randomized Trial of Targeted Transendocardial Delivery of Mesenchymal Precursor Cells in High-Risk Chronic Heart Failure Patients with Reduced Ejection Fraction (DREAM-HF)

DREAM-HF试验：高危慢性HFrEF患者经心内膜靶向输送间充质前体细胞的随机试验

 

LBS 6：预防心血管疾病的方法：鱼油、可可和胆固醇？

1.Icosapent Ethyl Versus Placebo in Outpatients with Covid-19: The Main Results of PREPARE-IT 2

 REPARE-IT 2试验的主要结果：在COVID-19门诊患者中，Icosapent Ethyl vs 安慰剂

 

2. Primary Findings from the Cocoa Supplement and Multivitamin Outcomes Study (COSMOS) on the Prevention of Cardiovascular Disease

COSMOS试验：可可补充剂和多维在预防心血管疾病方面的主要发现

 

3. The Clinical Safety, Pharmacokinetics and LDL-Cholesterol Lowering Efficacy of MK-0616, an Oral PCSK9 Inhibitor

 口服PCSK9抑制剂MK-0616的临床安全性、药代动力学及降低低密度脂蛋白胆固醇的功效

 

LBS 7：心血管疾病的新药和新药适应证

 

1.Effects of Aspirin onDementiaand Cognitive Impairment in the ASCEND Trial

 ASCEND试验：阿司匹林对痴呆和认知功能的影响

 

2.P2y12 Inhibitors in Noncritically Ill Hospitalized Patients with Covid-19 (ACTIV-4A)

ACTIV-4A试验：P2Y12抑制剂在非危重症住院COVID-19患者中的作用

 

3.Effect Of Bentracimab on Platelet Inhibition and Hemostasis in Ticagrelor Patients with Uncontrolled Hemorrhage or Requiring Urgent Surgery in the REVERSE-IT

REVERSE-IT试验：Bentracimab对发生不可控出血或需要紧急手术的替格瑞洛患者的血小板抑制和止血的影响

 

4.Milvexian for Prevention of Venous Thromboembolism After Elective Knee Arthroplasty: The AXIOMATIC-TKR Study

 AXIOMATIC-TKR试验：择期膝关节置换术后，Milvexian用于预防静脉血栓栓塞的疗效

 

医脉通编译自：AHA announces late-breaking science lineup to be presented during the virtual meeting. Healio. October 03, 2021.

(本网站所有内容，凡注明来源为“医脉通”，版权均归医脉通所有，未经授权，任何媒体、网站或个人不得转载，否则将追究法律责任，授权转载时须注明“来源：医脉通”。本网注明来源为其他媒体的内容为转载，转载仅作观点分享，版权归原作者所有，如有侵犯版权，请及时联系我们。)